IGC Pharma, Inc. (IGC)
NYSEAMERICAN: IGC · Real-Time Price · USD
0.2566
+0.0067 (2.68%)
Aug 7, 2026, 4:00 PM EDT - Market closed
IGC Pharma Financials Overview
Financials in millions USD. Fiscal year is April - March.
Millions USD. Fiscal year is Apr - Mar.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '25 Sep 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
Revenue Revenue Growth | 1.11 | 1.27 | 1.35 | 0.91 | 0.4 | 0.9 |
Revenue Growth | -6.51% | -5.50% | 47.64% | 129.47% | -55.79% | -77.95% |
Gross Profit Gross Profit Growth | 0.51 | 0.62 | 0.73 | 0.44 | 0.19 | 0.11 |
Operating Income Operating Income Growth | -8.09 | -7.45 | -9.8 | -11.57 | -15.43 | -8.72 |
Net Income Net Income Growth | -6.45 | -7.12 | -13 | -11.51 | -15.02 | -8.81 |
Earnings Per Share EPS Growth | -0.07 | -0.09 | -0.22 | -0.22 | -0.30 | -0.21 |
EPS Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '25 Sep 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
United States of America United States of America Growth | 1.11 | 1.27 | 1.18 | 0.78 | 0.33 | 0.72 |
Colombia Colombia Growth | - | 0 | 0 | 0.02 | - | - |
India India Growth | - | - | 0.16 | 0.11 | 0.07 | 0.18 |
Total Total Growth | 1.11 | 1.27 | 1.35 | 0.91 | 0.4 | 0.9 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '25 Sep 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
Cash & Investments Cash & Investments Growth | 1.13 | 0.41 | 1.2 | 3.35 | 10.46 | 14.63 |
Total Debt Total Debt Growth | 0.14 | 0.14 | 0.22 | 0.35 | 0.49 | 0.99 |
Net Cash (Debt) Net Cash Growth | 0.99 | 0.26 | 0.98 | 3 | 9.98 | 13.64 |
Net Cash Growth | -27.83% | -73.29% | -67.45% | -69.91% | -26.89% | 15.58% |
Net Cash Per Share Net Cash Per Share Growth | 0.01 | 0.00 | 0.02 | 0.06 | 0.20 | 0.33 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '25 Sep 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | -5.54 | -4.8 | -5.2 | -7.05 | -7.46 | -10.8 |
Capital Expenditures CapEx Growth | -0.08 | -0.11 | -0.14 | -0.31 | -0.24 | -1.47 |
Free Cash Flow Free Cash Flow Growth | -5.63 | -4.91 | -5.34 | -7.36 | -7.7 | -12.27 |
Free Cash Flow Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '25 Sep 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
Gross Margin | 46.20% | 48.70% | 54.50% | 48.52% | 48.87% | 12.58% |
Operating Margin | -731.83% | -585.84% | -728.48% | -1270.14% | -3886.15% | -971.49% |
Pretax Margin | -582.82% | -560.27% | -966.54% | -1263.01% | -3782.37% | -981.18% |
Profit Margin | -582.82% | -560.27% | -966.54% | -1263.01% | -3782.37% | -981.18% |
FCF Margin | -508.68% | -386.07% | -396.80% | -807.57% | -1939.04% | -1366.37% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 8, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
Forward PE | - | 4.35 | 4.35 | 4.35 | 4.35 | 4.35 |
PS Ratio | 23.22 | 18.14 | 19.83 | 19.78 | 122.03 | 95.34 |